Inluriyo for Breast Cancer: 6 Essential Facts to Know
Inluriyo for breast cancer: who qualifies, how imlunestrant works, the 400 mg daily dose, ESR1 testing, side effects, cost factors and warning signs.

Introduction
Inluriyo (imlunestrant) is a once-daily pill for a specific type of advanced breast cancer. The FDA approved it on September 25, 2025, for adults with estrogen receptor (ER)-positive, HER2-negative breast cancer that has spread or cannot be removed with surgery, carries a mutation in the ESR1 gene, and has grown despite at least one previous hormone (endocrine) therapy. In September 2026, the FDA expanded the label to include use together with abemaciclib in the same group of patients.
For people whose cancer has stopped responding to standard hormone therapy, a new oral option can matter a great deal. This guide covers six essential facts about Inluriyo, based on the FDA-approved prescribing information and FDA's approval summary: what it is, how it works, how it is taken, side effects, cost factors and who qualifies. It is meant to support, not replace, conversations with your oncology team.
1. What Is Inluriyo and Why Does It Matter for Breast Cancer Treatment?

Inluriyo is an estrogen receptor antagonist taken by mouth. It is often described as an oral selective estrogen receptor degrader, or SERD, because it both blocks the estrogen receptor and helps the cell break it down.
Understanding hormone receptor-positive breast cancer
About two out of three breast cancers are hormone receptor-positive, meaning estrogen helps them grow. Treatments that lower estrogen or block its receptor are the backbone of care for this type. Knowing the exact type of breast cancer, including its receptor status and mutations, guides the right treatment.
Why endocrine therapy resistance happens
Over time, many advanced cancers stop responding to hormone therapy. One common reason is a mutation in ESR1, the gene that makes the estrogen receptor. These mutations often appear after treatment with aromatase inhibitors and allow the receptor to stay switched on even when estrogen levels are very low.
Who may benefit from Inluriyo?
Inluriyo is designed for cancers with ESR1 mutations. Because it targets the receptor itself rather than estrogen supply, it can still work when the receptor has changed.
| Feature | Details |
|---|---|
| Active ingredient | Imlunestrant |
| Drug type | Oral selective estrogen receptor degrader (SERD) |
| Main use | Certain advanced or metastatic breast cancers |
| Target | Estrogen receptor pathway |
| Common cancer type | HR-positive, HER2-negative breast cancer |
2. How Does Inluriyo Work for Breast Cancer?

Inluriyo as an estrogen receptor degrader
Imlunestrant attaches to the estrogen receptor, blocks its activity and marks it for breakdown. With fewer working receptors, cancer cells lose a key growth signal.
Benefits shown in clinical studies
The approval was based on EMBER-3, a randomized trial in people with ER-positive, HER2-negative advanced breast cancer that had progressed after an aromatase inhibitor, with or without a CDK4/6 inhibitor. In the 256 patients with ESR1 mutations, FDA reports that:
- Median progression-free survival was 5.5 months with Inluriyo versus 3.8 months with the doctor's choice of standard hormone therapy.
- The risk of the cancer growing or death was reduced by 38% (hazard ratio 0.62).
- Tumors shrank in 14.3% of people on Inluriyo compared with 7.7% on standard therapy.
Overall survival data were not yet mature at the time of approval.
Oral treatment advantages
The older SERD, fulvestrant, is given as monthly injections into the buttock muscles. Inluriyo is taken at home as tablets, which many people find more convenient.
| Treatment Type | How It Works | Administration |
|---|---|---|
| Aromatase inhibitors | Reduce estrogen production | Oral tablets |
| SERMs | Block estrogen receptors | Oral tablets |
| Injectable SERDs | Degrade estrogen receptors | Injection |
| Inluriyo (Imlunestrant) | Oral estrogen receptor degradation | Oral tablet |
3. What Is the Inluriyo Dosage and How Is It Taken?

How is Inluriyo taken?
The recommended dose is 400 mg by mouth once a day, taken as two 200 mg tablets, until the cancer progresses or side effects become too difficult. Key instructions from the label:
- Take it on an empty stomach, at least two hours before food or one hour after food.
- Take it at about the same time each day.
- Swallow tablets whole. Do not split, crush or chew them.
- People with moderate or severe liver impairment are usually given a lower dose of 200 mg once daily.
- If you miss a dose by six hours or more, or vomit after taking it, skip it and take the next dose at the usual time the following day.
People with moderate or severe liver problems usually take a lower dose of 200 mg daily. Your doctor may also lower the dose if side effects occur.
Monitoring during treatment
Expect regular blood tests for blood counts, liver enzymes and cholesterol and triglyceride levels, plus scans to see how the cancer is responding.
Importance of medical supervision
Inluriyo interacts with some medicines, especially strong CYP3A inhibitors or inducers, which change how much drug reaches the blood. Tell your team about every prescription, over-the-counter medicine and supplement you take, including herbal products such as St. John's wort. Premenopausal and perimenopausal women, and men, typically also receive a medicine that suppresses hormone production from the ovaries or testes.
4. What Are the Side Effects of Inluriyo?

Common Imlunestrant side effects
In the trial, the most common side effects and lab changes (in at least 10% of people taking Inluriyo alone) included:
- Musculoskeletal pain
- Fatigue
- Diarrhea, nausea, constipation and abdominal pain
- Lower hemoglobin, neutrophils, platelets and calcium on blood tests
- Raised liver enzymes (AST and ALT)
- Higher triglycerides and cholesterol
Serious reactions requiring medical advice
Inluriyo can harm an unborn baby. People who could become pregnant, and men with partners who could, should use effective contraception during treatment and for one week after the last dose, as advised in the label. When Inluriyo is combined with abemaciclib, the label says to follow whichever medicine calls for the longer period after stopping, so ask your care team how long to continue birth control and avoid breastfeeding. Tell your team right away about yellowing of the skin or eyes, dark urine or severe tiredness, which may point to liver problems.
Managing treatment-related symptoms
Gentle activity, a regular sleep routine and small, frequent meals can ease fatigue and nausea. Our article on what to eat when you have no appetite has practical ideas. Ask before using any anti-diarrhea medicine or supplement.
5. How Much Does Inluriyo Cost and What Affects Pricing?

Factors affecting Inluriyo cost
Inluriyo is a new brand-name cancer drug, so the list price is high. What you actually pay depends on your insurance plan, whether it is covered as a specialty drug, your deductible and coinsurance, and the pharmacy used. Prices change, so check current figures with your insurer and pharmacy rather than relying on online estimates.
Discussing affordability with your care team
Oncology clinics often have financial counselors who can help with prior authorization and appeals. Ask early, before the first fill.
Planning treatment expenses
Options can include manufacturer support programs, independent cancer charities and Medicare Part D assistance programs. Remember to budget for blood tests, scans and visits as well as the medicine. Our guide on how to advocate for yourself offers tips for these conversations.
6. Who Qualifies for Inluriyo Treatment?

Typical eligibility considerations
Under the current FDA label, Inluriyo, alone or with abemaciclib, is for adults whose breast cancer is:
- ER-positive and HER2-negative
- Advanced or metastatic
- ESR1-mutated, confirmed by an FDA-authorized test
- Progressing after at least one line of endocrine therapy
Role of ESR1 mutation testing
The ESR1 mutation is detected with a blood-based (liquid biopsy) test. FDA approved the Guardant360 CDx assay as a companion test alongside Inluriyo. Because ESR1 mutations can develop during treatment, testing is often repeated when cancer progresses.
Importance of personalized cancer care
Inluriyo is one of several options for ESR1-mutated disease. Your oncologist will consider prior treatments, other mutations, symptoms and your goals when recommending the next step.
When to See a Doctor
Contact your oncology team promptly if you have:
- Diarrhea, nausea or vomiting that keeps you from eating or drinking
- Yellowing skin or eyes, dark urine or pain in the upper right abdomen
- Fever or chills, which may signal infection when blood counts are low
- Unusual bruising or bleeding
- New or worsening bone pain, headaches or shortness of breath
Emergency: Call 911 (or your local emergency number) if you have chest pain, severe trouble breathing, signs of a stroke such as sudden weakness or trouble speaking, heavy bleeding or fainting.
Conclusion
Inluriyo gives people with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer an oral option after hormone therapy stops working. It is taken as 400 mg once daily on an empty stomach, requires an ESR1 blood test to confirm eligibility, and needs regular monitoring for blood count, liver and lipid changes. Working closely with your oncology team, including on cost and side-effect management, helps you get the most from treatment.
Sources
- FDA Approves Imlunestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer (FDA)
- Inluriyo (imlunestrant) Prescribing Information, Revised 09/2026 (FDA)
- Drug Trials Snapshots: Inluriyo (FDA)
- Hormone Therapy for Breast Cancer (National Cancer Institute)
- Breast Cancer Treatment (PDQ) (National Cancer Institute)
FAQ
1. What is Inluriyo used for?
Inluriyo treats adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed after at least one hormone therapy. It can be used alone or with abemaciclib.
2. When did the FDA approve Inluriyo?
The FDA approved Inluriyo on September 25, 2025. Use in combination with abemaciclib was added to the label in September 2026.
3. How should Inluriyo be taken?
Take 400 mg (two 200 mg tablets) by mouth once daily on an empty stomach, at least two hours before or one hour after food, and swallow the tablets whole.
4. Do I need a test before starting Inluriyo?
Yes. An FDA-authorized blood test must show an ESR1 mutation. The Guardant360 CDx assay was approved as a companion test.
5. What are common side effects of Inluriyo?
Common effects include muscle and joint pain, fatigue, diarrhea, nausea and changes in blood counts, liver enzymes and cholesterol or triglycerides on blood tests.
About the author

Health Researcher and Writer
Haider Nadeem is a health researcher and the writer behind Healthy Eats Guide. He writes about health problems he faces or sees people around him face, and turns careful research into practical guides. Articles are researched and drafted with AI assistance, then fact-checked and edited by Haider using cited sources such as USDA, NIH, and peer-reviewed research.
Related blogs

3 Types of Skin Cancer: Essential Facts You Must Know
3 types of skin cancer explained: how basal cell, squamous cell and melanoma look, the ABCDEs, diagnosis, treatment, survival and simple prevention steps.
10 min read

Mounjaro Fatigue: 5 Essential Facts to Know
Mounjaro fatigue explained: what the FDA label says, 5 key facts about tirzepatide tiredness, common causes like low intake and dehydration, and when to seek care.
9 min read

Exdensur for Asthma: 7 Essential Facts to Know
Exdensur for asthma explained: how depemokimab works, who qualifies, the twice-yearly dosing schedule, trial results, side effects and its nasal polyp status.
10 min read
Newsletter
Get practical nutrition guides in your inbox
Clear food-by-food advice and diet tips for everyday eating — no spam, unsubscribe anytime.